重组人血管内皮抑制素联合化疗治疗非小细胞肺癌的临床研究

Effect of recombinant human endostatin combined with chemotherapy treatment on non-small cell lung cancer

目的评价重组人血管内皮抑制素联合化疗治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法 86例NSCLC患者随机分为对照组(42例)和观察组(44例),对照组进行常规化疗,观察组在常规化疗基础上,联合重组人血管内皮抑制素治疗,3周为一个疗程,至少治疗2个疗程,主要观察指标为治疗效果、Karnofsky评分、体重指数、疾病进展时间(TTP)及不良反应等。结果观察组总有效率为43.18%(19/44),高于对照组的26.19%(11/42)(P<0.05)。2组完全缓解(CR)、部分缓解(PR)、稳定(SD)及进展(PD)差异无统计学意义(P>0.05)。观察组Karnofsky评分,体重指数和TTP均高于对照组(P<0.05)。2组恶心呕吐、肝功能损害及骨髓抑制等不良反应差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素联合化疗治疗中晚期NSCLC可有效提高临床疗效,且未增加药物不良反应。

Objective To explore the clinical effects of recombinant hu-man endostatin combined with chemotherapy treatment on non small cell lung cancer （ NSCLC ）.Methods Eighty -six patients with NSCLC were selected and randomly divided into the control group （ n=42 ） and the observation group （ n=44 ）.The control received conventional chem-otherapy, while the observation group was treated with recombinant human endostatin on the basis of the conventional chemotherapy.Three weeks was a treatment cycle and the treatment lasted at least 2 cycles.Main indexes were effects of treatment , KPS score, body mass index （BMI）, time of the disease progression （ TTP） and adverse reactions.Results The total effective rate of the observation group was 43.18%（19/44）, higher than that of control group 26.19% （11/42）.The difference was statistically significant （ P〈0.05 ）.The complete remis-sion （ CR） , partial remission （ PR） , stability disease （ SD） and progress disease（PD） were no significant difference of two groups （P〉0.05）.KPS score and BMI of the observation group were higher than those of the control group （ P〈0.05 ）.TTP of the observation group was longer than that of the control group , the difference was significant statistically （ P〈0.05 ）.Compared with nausea and vomiting , liver function damage and inhibition of bone marrow and other adverse reaction results of two groups ,＆amp;nbsp;and there was no significant difference （ P 〉0.05 ）.Conclusion Recombinant human endostatin combined with chemotherapy treatment on advanced NSCLC could improve the clinical efficacy effectively , without increasing adverse reactions.